Article
Nintedanib and Pirfenidone Affect Growth and Differentiation of Human Alveolar Type 2 Cells
2026-03-03
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Background</h4> Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease characterized by epithelial cell senescence. Pirfenidone and nintedanib are approved drugs for the treatment of IPF. They significantly slow disease progression, but their mechanisms of action, especially on alveolar type 2 (AT2) cells, are poorly understood. We addressed this question by evaluating c...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 69b7cb63-161a-5c4e-b9ac-a2b6b08248fb
- DOI
- 10.64898/2026.03.02.708135
